View Older Stories View More Recent Stories

Jul 23, 2023 05:00PM Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
Jul 21, 2023 05:02PM Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
Jul 20, 2023 12:00PM Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
Jul 19, 2023 08:30AM Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
Jul 14, 2023 04:05PM Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023
Jul 14, 2023 08:03AM Gilead Sciences (GILD) Announces FDA Approval of Veklury for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
Jul 14, 2023 08:00AM FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
Jul 13, 2023 06:02AM Gilead Sciences (GILD) Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
Jul 13, 2023 06:00AM Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
Jun 23, 2023 08:12AM Gilead Sciences (GILD) Receives CHMP Positive Opinion for Trodelvy in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Jun 23, 2023 08:11AM Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Jun 23, 2023 02:30AM Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks
Jun 15, 2023 04:01PM Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
Jun 14, 2023 03:00AM Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
Jun 6, 2023 10:47AM Gilead's(GILD) Kite's Tecartus CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate
Jun 6, 2023 10:45AM Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma
Jun 5, 2023 12:34PM Gilead Sciences (GILD) Announces Trodelvy Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Jun 5, 2023 12:30PM Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Jun 5, 2023 11:25AM Gilead (GILD) Announces Kite’s Yescarta CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of R/R Large B-cell Lymphoma
Jun 5, 2023 11:25AM Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
Jun 3, 2023 01:30PM Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
Jun 1, 2023 08:34AM Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
May 26, 2023 01:00AM CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
May 25, 2023 04:05PM Gilead Sciences to Present at Upcoming Investor Conference
May 17, 2023 08:30AM Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
May 16, 2023 04:02PM Gilead Sciences (GILD) Appoints Cindy Perettie as EVP of Kite
May 16, 2023 04:01PM Gilead Appoints Cindy Perettie Executive Vice President of Kite
May 15, 2023 08:30AM Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
May 9, 2023 08:31AM Gilead Sciences (GILD) Announces Acquisition of XinThera
May 9, 2023 08:30AM Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
May 4, 2023 07:02AM Gilead Sciences (GILD) Reports Positive CHMP Opinion for Hepcludex
May 4, 2023 07:00AM CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
May 1, 2023 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Apr 16, 2023 04:00AM Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations
Apr 13, 2023 04:05PM Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023
Mar 29, 2023 10:35AM Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
Mar 22, 2023 12:00PM Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
Mar 21, 2023 09:38AM Gilead Sciences (GILD) Announces Kite's Yescarta CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in OS for Initial Treatment of R/R Large B-cell Lymphoma
Mar 21, 2023 09:37AM Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
Mar 20, 2023 08:30AM Gilead Sciences (GILD) Exercises Option to License Nurix’s (NRIX) NX-0479
Mar 20, 2023 08:30AM Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
Mar 20, 2023 08:30AM Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
Feb 22, 2023 11:21AM Gilead Sciences (GILD) Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the
Feb 22, 2023 11:21AM Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV
Feb 22, 2023 09:03AM Gilead Sciences' (GILD) Kite Completes Acquisition of Tmunity
Feb 22, 2023 09:00AM Kite Completes Acquisition of Tmunity
Feb 21, 2023 05:30PM Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients
Feb 21, 2023 03:01PM Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies
Feb 17, 2023 09:00AM Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
Feb 14, 2023 08:45AM Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
View More Recent Stories View Older Stories